4.7 Article

Outcomes and Risk Factors in Patients with Multiple Primary Melanomas

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 139, Issue 1, Pages 195-201

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2018.07.009

Keywords

-

Categories

Funding

  1. University of California, San Francisco Dermatology Department funds
  2. US Department of Health and Human Services
  3. National Institutes of Health
  4. National Center for Advancing Translational Sciences
  5. Marcus Seeding Bold Ideas Initiative
  6. Helen Diller Family Comprehensive Cancer Center Impact Award
  7. UCSF Helen Diller Family Comprehensive Cancer Center Impact Grant Award
  8. Science Without Borders Scholarship/CAPES-Brazil
  9. Turkish Society of Dermatology
  10. [UL1TR000004]
  11. [K76AG054631]
  12. [R21CA212201]
  13. [DP2OD024079]

Ask authors/readers for more resources

The incidence and patient survival rates of melanoma have increased over the last several decades, with a growing population of patients who develop multiple primary melanomas (MPMs). To determine risk factors for developing MPMs and compare the survival of patients with MPMs to those with single primary melanomas, a prospective, multidisciplinary database of patients with melanoma at a single tertiary care institution was retrospectively reviewed. From 1985 to 2013, 6,963 patients with single primary melanomas and 305 patients with MPMs were identified. Mean follow-up was 8.3 +/- 6.3 years for patients with single primary melanomas and 8.8 +/- 5.9 years for patients with MPMs. Risk of developing multiple melanomas increased with age at diagnosis of first melanoma (hazard ratio [HR] = 1.20 for a 10-year increase in age, 95% confidence interval [CI] = 1.11-1.29, P < 0.001), male sex (HR = 1.44, 95% CI = 1.12-1.84, P = 0.005), and white race (HR = 3.07, 95% CI = 1.45-6.51). Patients with invasive MPMs had increased risk of melanoma-specific death both before (HR = 1.47, 95% CI = 1.0-2.2) and after adjusting for age, sex, site, race, family history of melanoma, personal history of other cancer, and Surveillance, Epidemiology, and End Results Program (SEER) stage (HR = 1.44, 95% CI = 0.95-2.2); however, this result did not reach statistical significance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available